You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Quantitative Optical Sensor to Monitor Pre-Clinical Tumor Vascular Physiology

    SBC: Zenalux Biomedical, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Angiogenesis and hypoxia can significantly influence the efficacy of therapy and the behavior of surviving tumor cells. This important fact is supported by a vast amount of literature on pre-clinical models and clinical studies. There is growing demand for technologies to measure tumor hypoxia and angiogenesis temporally and spatially in vivo to enable advance ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. A Universal Brain Atlas for Implanting and Managing Deep Brain Stimulators

    SBC: Neurotargeting, LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): Deep brain stimulation has risen as a neurosurgical procedure of choice for patients with disabling neurological or psychiatric disorders for its abiliy to modulate improvement in the activity of certain circuits. The procedure is currently approved for treatment of Parkinson's disease (PD), essential tremor (ET), dystonia, and obsessive-compulsive disorde ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. CMV Therapeutic Vaccine for the Treatment of Glioblastoma

    SBC: Annias Immunotherapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Recently, temozolomide (TMZ), a myelosuppressive alkylating chemotherapy, has shown a benefit in patients with glioblastoma multiformes (GBM), but median survival is still less than 15 months. Moreover, these conventional chemotherapies lack specificity and result in incapacitating damage to surrounding normal brain and systemic tissues. Immunotherapy may provi ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Delivery system development for a reservoir targeted Lyme disease vaccine

    SBC: FoodSource Lure Corporation            Topic: NIAID

    DESCRIPTION (provided by applicant): The incidence and geographic distribution of Lyme disease in the U.S. has increased steadily since its first description in 1977. Efforts to stem the spread of the disease through controlling the population of its tickvector and/or the mouse reservoirs of the disease have met with only limited success. The only approved human vaccine to protect against Lyme di ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Novel Class for Opioid Drugs

    SBC: ALGYNOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): The mu-opioid receptor (MOR) is the primary target for opioid analgesics. While opioids are the most frequently used and effective analgesics for the treatment of moderate to severe clinical pain, their prolonged use leads to reduced efficacy and a number of adverse side effects, including post dosing-induced hyperalgesia and analgesic tolerance. MOR induces an ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a novel method for inhibiting diabetic retinopathy

    SBC: VASCULAR PHARMACEUTICALS            Topic: NEI

    DESCRIPTION (provided by applicant): The long-term objective of the proposed study is to develop a monoclonal antibody that inhibits the progression of diabetic retinopathy. Insulin-like growth factor-I (IGF-I) has been implicated in both endothelial dysfunction as well as the proliferative phase of the disease. However directly inhibiting the IGF-I receptor may be lead to neurotoxicity. Following ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Extended NeuroAmides: Novel Antiepileptic Drug Candidates

    SBC: NeuroGate Therapeutics, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Epilepsy is a set of disorders that result from neuronal hyperexcitability and hypersynchronous neuronal firing. Epilepsy remains a major widespread neurological concern. Current medications do not meet the health needsof 30% of epilepsy patients, and approximately 40% of patients experience serious side effects. So, the need for novel, more effective therapies ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. External Glaucoma Drainage Device

    SBC: CAMRAS VISION, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Glaucoma is one of the leading causes of blindness in the world affecting 67 million people. Reduction of intraocular pressure (IOP) is the only proven treatment for delaying the progression of vision loss caused by glaucoma. The current surgical options for IOP lowering are unpredictable and suboptimal in terms of success rate. One of the primary reasons for s ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Fast Algorithms for Generating Hardbody Thermal Histories

    SBC: Aegis Technologies Group, LLC, The            Topic: MDA10T003

    The results of the Phase I effort has identified the feasibility of real-time hardbody thermal solver algorithms on high performance hardware for use by MDA applications and real-time hardware-in-the-loop environments. Phase II development of the thermal solver will be expanded to include complex targets by expanding upon the techniques prototyped in Phase I. A new inline Parallel Euler Solver w ...

    STTR Phase II 2012 Department of DefenseMissile Defense Agency
  10. Improved Multi Junction Solar Cell Technology for Satellites

    SBC: CFD RESEARCH CORPORATION            Topic: MDA09T005

    Higher efficiency solar cells are needed to reduce mass, volume, and cost of DoD space missions. However, to achieve higher efficiency and radiation hardness of the best to date multi-junction photovoltaic (MJ PV) devices, several challenges must be addressed. This project aims to develop: 1) Quantum Well (QW)-based multi-junction cell technology that exhibits enhanced efficiency, and 2) Radiation ...

    STTR Phase II 2012 Department of DefenseMissile Defense Agency
US Flag An Official Website of the United States Government